Therapeutics Anti-Infective and Anti-Inflammatory Agents

Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant

Empson M, Lassere M, Craig J, Scott J

Published April 18, 2005 The Cochrane database of systematic reviews, 2005(2), CD002859
DOI 10.1002/14651858.CD002859.pub2 PMID 15846641 PMC PMC6768987

RRM Academy Synopsis

Unfractionated heparin plus aspirin may reduce pregnancy loss by 54%

Unfractionated heparin plus aspirin may reduce pregnancy loss by 54% compared with aspirin alone. Two small trials in a Cochrane review of 13 trials reported this. The 849 participants were pregnant women with antiphospholipid antibody and earlier pregnancy loss. Aspirin alone did not significantly reduce loss. Prednisone plus aspirin significantly increased prematurity in three trials.

Key Findings

  • Unfractionated heparin plus aspirin against aspirin alone, two trials with 140 women: relative risk (RR) of pregnancy loss 0.46, 95% confidence interval (CI) 0.29 to 0.71.
  • Low molecular weight heparin (LMWH) plus aspirin, tested against aspirin in one trial with 98 women, gave a loss risk that was not significantly different (RR 0.78, 95% CI 0.39 to 1.57).
  • Aspirin alone was tested in three trials with 135 women. Pregnancy loss was about the same as in the comparison groups (RR 1.05, 95% CI 0.66 to 1.68).
  • Prednisone plus aspirin, three trials with 286 women, brought more premature delivery and more gestational diabetes, with no significant benefit in pregnancy loss.
  • Intravenous immunoglobulin was associated with a higher risk of pregnancy loss or premature birth than heparin plus aspirin (two trials, 58 women; RR 2.51, 95% CI 1.27 to 4.95).

Interpretation

This Cochrane review pooled randomized and quasi-randomized trials. Heparin plus aspirin lowered pregnancy loss compared with aspirin alone. Low molecular weight heparin plus aspirin did not lower loss by a clear margin. Aspirin alone also did not lower loss. Prednisone plus aspirin raised rates of early delivery and gestational diabetes, with no drop in pregnancy loss. Intravenous immunoglobulin was linked with more loss or early birth than heparin plus aspirin. The authors call for larger trials to confirm these findings.

RRM Context

Testing can find antiphospholipid antibody in women with recurrent pregnancy loss. The review background reports a prevalence of 2.7% to 7% for anticardiolipin antibodies in general obstetric clinics. Restorative reproductive medicine looks for the cause before choosing treatment. A loss with no cause found is undiagnosed.

Abstract

Background

A range of treatments have been proposed to improve pregnancy outcome in recurrent pregnancy loss associated with antiphospholipid antibody (APL). Small studies have not resolved uncertainty about benefits and risks.

Objectives

To examine outcomes of all treatments given to maintain pregnancy in women with prior miscarriage and APL.

Search Strategy

We searched the Pregnancy and Childbirth Group's Trials Register (30 May 2004), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 2, 2003), MEDLINE (1966 to June 2003), EMBASE (1988 to June 2003), Lupus (volume one to eight, 1991 to 1999) and conference proceedings from the International Symposium on APL up to 1999.

Selection Criteria

Randomised or quasi-randomised, controlled trials of interventions in pregnant women with a history of pregnancy loss and APL.

Data Collection and Analysis

Two review authors independently assessed quality and extracted data for studies up to December 1999. One review author performed this for studies after 1999.

Main Results

Thirteen studies were found (849 participants). The quality was not high; 50% had clear evidence of allocation concealment. Participant characteristics varied between trials. Unfractionated heparin combined with aspirin (two trials; n = 140) significantly reduced pregnancy loss compared to aspirin alone (relative risk (RR) 0.46, 95% confidence interval (CI) 0.29 to 0.71). Low molecular weight heparin (LMWH) combined with aspirin compared to aspirin (one trial; n = 98) did not significantly reduce pregnancy loss (RR 0.78, 95% CI 0.39 to 1.57). There was no advantage in high-dose, over low-dose, unfractionated heparin (one trial; n = 50). Three trials of aspirin alone (n = 135) showed no significant reduction in pregnancy loss (RR 1.05, 95% CI 0.66 to 1.68). Prednisone and aspirin (three trials; n = 286) resulted in a significant increase in prematurity when compared to placebo, aspirin, and heparin combined with aspirin, and an increase in gestational diabetes, but no significant benefit. Intravenous immunoglobulin +/- unfractionated heparin and aspirin (two trials; n = 58) was associated with an increased risk of pregnancy loss or premature birth when compared to unfractionated heparin or LMWH combined with aspirin (RR 2.51, 95% CI 1.27 to 4.95). When compared to prednisone and aspirin, intravenous immunoglobulin (one trial; n = 82) was not significantly different in outcomes.

Authors' Conclusions

Combined unfractionated heparin and aspirin may reduce pregnancy loss by 54%. Large, randomised controlled trials with adequate allocation concealment are needed to explore potential differences between unfractionated heparin and LMWH.

Topics

By this author

Related research

Therapeutics › Anti-Infective and Anti-Inflammatory Agents › Immune Modulating Agents · Pregnancy › Pregnancy Complications › Hypertensive Disorders · Genetics and Immunology › Reproductive Immunology › Antiphospholipid Syndrome and Thrombophilia
Marianne B Empson, Marissa Lassere, Jonathan C Craig, James R Scott
M Empson, M Lassere, Jon Craig, J Craig, Jim Scott, Jimmy Scott, J Scott
PMID 15846641 15846641 DOI 10.1002/14651858.CD002859.pub2 10.1002/14651858.CD002859.pub2 Empson et al. 2005, Empson 2005